# AbCellera Biologics share price today (AbCellera Biologics Inc., ABCL)

> AbCellera Biologics Inc.'s P/E is near the low end of its own history, higher than only 14% of past readings, and its quarterly results are still getting worse. ABCL · Healthcare · Biotechnology · data as of 5 November 2026. Page: https://www.sectoralpha.in/us/stocks/abcl

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $11.13 (+184.7% in a year)
- P/E: 12.3× (lower than 86% of the last 1 year)
- Revenue (Jun 2026): $4.0 M (−76.3% on a year ago)
- Profit (Jun 2026), incl. one-off: −$55.4 M (one-off item, see below)
- Operating margin: −1,550.0% (−1,259.8 points on a year ago)
- ROE: −15%, FY25
- ROIC: −42.3%, against a 11.6% cost of capital: −53.9 points
- Profit that came in as cash: 167%, last 2 years

The main question: the P/E is near the low end of its own history, higher than only 14% of past readings, but results are getting worse. A low multiple can stay low until the quarters turn. ## What is the AbCellera Biologics share price today? AbCellera Biologics Inc.'s share price was $11.13 at the close on 5 November 2026. It has been rising for 25 weeks. That is 59.0% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $14, and at that close it sat 76% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 28 weeks in a row. Over the last 5.9 years the share price moved −77% while the S&P 500 moved +99%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does AbCellera Biologics pay? AbCellera Biologics Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is AbCellera Biologics on? AbCellera Biologics is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is AbCellera Biologics profitable? AbCellera Biologics Inc. posted a net loss of $55.4 M in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of $146 M. That loss is 1,368.6% of the quarter's revenue. The same quarter a year earlier lost $34.7 M. 12 of the last 12 reported quarters were loss-making. Read this profit with care: at −$55.4 M it is bigger than the quarter's whole revenue of $4.0 M. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −1,550.0% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. ## How much revenue does AbCellera Biologics make, and is it growing? AbCellera Biologics Inc. reported $4.0 M of revenue in the Jun 2026 quarter, −76.3% on the same quarter a year earlier. Over 4 years it has grown −33.1% a year on average. The last full year, FY25, came in at $75.1 M. The last four reported quarters add to $66.2 M. FY25 revenue was $75.1 M, +160.6% on the year before. Recent pace: the last four quarters grew +211.5% on average, against −33.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +101.3%, against +41.5% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does AbCellera Biologics keep? AbCellera Biologics Inc.'s operating margin was −1,550.0% in the Jun 2026 quarter, 1,259.8 percentage points lower than the same quarter a year ago. Across 5 years it has been between −980.7% and 54.5%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −1,259.8 percentage points on the year while gross margin changed −906.0 points. So the drop came mostly from the gross margin, which means input costs and prices charged. ## Is AbCellera Biologics' profit turning into cash? Over the last 2 years, 167% of AbCellera Biologics Inc.'s reported profit came in as cash from its operations, so the profit is backed by cash. In FY25 its operations used $131 M of cash, against −$146 M of profit. After $42.8 M of spending on assets, free cash was −$174 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does AbCellera Biologics' cash go? AbCellera Biologics Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $198 M on assets over the last 3 years. Averaged over those years that is 87.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $198 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is AbCellera Biologics' P/E ratio, and how does it compare with its own history? AbCellera Biologics Inc.'s P/E is 12.3×, near the low end of its own history: it has been lower only 14% of the time. Its usual P/E (the middle reading) is 15.0×, over 1 year of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. In short: the multiple is low against its own past, so the earnings trend underneath matters more than the multiple. ## Is the AbCellera Biologics business getting better or worse? AbCellera Biologics Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does AbCellera Biologics earn on its capital? AbCellera Biologics Inc. earned a ROE of −15% in FY25. Its return on capital used (ROIC) is 53.9 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −194.9% net margin and 0.06× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −194.9% net margin × 0.06× asset turnover × 1.40× leverage (assets divided by equity) ≈ −16.4% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −42.3% − 11.6% = −53.9 percentage points. The 11.6% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −42.3% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −40.5%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does AbCellera Biologics have too much debt? AbCellera Biologics Inc. has total debt of $136 M against shareholder equity of $896 M as of Jun 2026, so its debt is 0.15× its equity, which is very little. Year by year, that ratio went from 0.04 in FY21 to 0.15 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the AbCellera Biologics shareholding pattern? 14.0% of AbCellera Biologics Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 5.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is AbCellera Biologics from balance-sheet trouble? For AbCellera Biologics Inc., the Z-score is 1.83. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the grey area between the two. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.83 is in the grey area, neither clearly safe nor clearly in trouble. ## How does AbCellera Biologics rank in its industry? There is no score against its industry: AbCellera Biologics Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is AbCellera Biologics compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to AbCellera Biologics in size? AbCellera Biologics is the 52nd largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Relay Therapeutics, Inc., ACADIA Pharmaceuticals Inc. and Xenon Pharmaceuticals Inc. Just below it: Tango Therapeutics, Inc., Iovance Biotherapeutics, Inc. and Arcutis Biotherapeutics, Inc. ### Biotechnology companies close in size

1. [Relay Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/rlay) $3.7 billion
2. [ACADIA Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/acad) $3.7 billion
3. [Xenon Pharmaceuticals Inc.](https://www.sectoralpha.in/us/stocks/xene) $3.6 billion
4. AbCellera Biologics Inc. $3.6 billion
5. [Tango Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/tngx) $3.5 billion
6. [Iovance Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/iova) $3.5 billion
7. [Arcutis Biotherapeutics, Inc.](https://www.sectoralpha.in/us/stocks/arqt) $3.4 billion

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Core Natural Resources, Inc.](https://www.sectoralpha.in/us/stocks/cnr) $4 billion · Thermal Coal
2. [Bread Financial Holdings, Inc.](https://www.sectoralpha.in/us/stocks/bfh) $4 billion · Credit Services
3. AbCellera Biologics Inc. $4 billion
4. [JOYY Inc.](https://www.sectoralpha.in/us/stocks/joyy) $4 billion · Internet Content & Information
5. [First BanCorp.](https://www.sectoralpha.in/us/stocks/fbp) $4 billion · Banks - Regional

## What else do people ask about AbCellera Biologics? ### What were AbCellera Biologics's latest quarterly results? AbCellera Biologics Inc. reported revenue of $4.0 M and a net loss of $55.4 M for the Jun 2026 quarter. Earnings per share were −$0.18. The operating margin was −1,550.0%, 1,259.8 percentage points lower than a year earlier (as of 5 November 2026). ### What is AbCellera Biologics's market cap? AbCellera Biologics Inc.'s market capitalisation is $3.6 B at a stock price of $11.13. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 5 November 2026). ### How is AbCellera Biologics performing? AbCellera Biologics Inc.'s share price has been rising for 25 weeks. Over the past 13 weeks it has done better than the S&P 500, for 28 weeks running. This describes what the data did, not a rating (as of 5 November 2026). ### Will AbCellera Biologics's stock price go up? This page does not forecast AbCellera Biologics Inc.'s stock price. What it shows instead: the stock price is $11.13, and it has been rising for 25 weeks. Its P/E of 12.3× is higher than 14% of its own last 1 years (as of 5 November 2026). ### Is AbCellera Biologics's profit real cash? Yes, over the last 2 years, 167% of AbCellera Biologics Inc.'s reported profit came in as cash from operations. The latest year was lower at 90%, so the trend is worth watching. In FY25, operating cash was −$131 M against reported profit of −$146 M. Most of that cash then goes into building new capacity. These are yearly figures (as of 5 November 2026). ### Where is AbCellera Biologics in its business cycle? AbCellera Biologics Inc.'s FY25 operating margin was −289.0%, against a 5-year range of −980.7% to 54.5%: the middle of its own range, neither a peak nor a low. The latest quarter was −1,550.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 5 November 2026). ### What could break the AbCellera Biologics story? The main question: the P/E is near the low end of its own history, higher than only 14% of past readings, but results are getting worse. A low multiple can stay low until the quarters turn. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 5 November 2026). ### Is AbCellera Biologics a stock worth studying right now? What the numbers show: AbCellera Biologics Inc.'s P/E is near the low end of its own history, higher than only 14% of past readings, and its quarterly results are still getting worse. The main open question: whether results start to improve. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 5 November 2026). This is research, not advice. We’re not SEBI-registered.